|
TABLE OF CONTENT: South African Journal of
Diabetes and Vascular Disease
Vol 2, Issue 3, Oct / Nov 2005
- Title: Tight glycaemic control : the key to
improving the management of type 2 diabetes : editorial
Authors: Alberti, George
From: South African Journal of Diabetes and Vascular
Disease, Vol 2, Issue 3, Oct / Nov
Published: 2005
Pages: p.103-104
Full text: Click here to order
Full text:
Click here to read online (Login Required)
- Title: Of adiposity, inflammation and new
treatments for type 2 diabetes : editorial
Authors: Distiller, Larry A.
From: South African Journal of Diabetes and Vascular
Disease, Vol 2, Issue 3, Oct / Nov
Published: 2005
Pages: p.106-108
Full text: Click here to order
Full text:
Click here to read online (Login Required)
- Title: Insulin secretion : function and therapy
of pancreatic beta-cells in diabetes : review
Authors: Rorsman, Patrik
From: South African Journal of Diabetes and Vascular
Disease, Vol 2, Issue 3, Oct / Nov
Published: 2005
Pages: p.109-113
Full text: Click here to order
Full text:
Click here to read online (Login Required)
Abstract: Insulin is secreted from the beta-cells of the
pancreatic islets in response to an elevation of blood
glucose concentration. This review describes a current view
of the metabolic control of insulin secretion and the
molecular mechanisms involved, including the role played by
the beta-cell to ensure correct release of insulin as a
result of electrical signals. It then considers what goes
wrong in type 2 diabetes, a disease resulting from
insufficient insulin secretion. It focuses on the influence
of genetics exploring the theory of a genetic predisposition
to type 2 diabetes, as well as the roles played by age and
obesity. Finally, the mode of action of the hypoglycaemic
sulphonylureas is discussed and the potential implications
for the beta-cell associated with a sulphonylurea-based
therapy.
- Title: Dual blockade of the renin angiotensin
system in diabetes - rationale and risks : review
Authors: Kumar, Rajeev; Winocour, Peter H.
From: South African Journal of Diabetes and Vascular
Disease, Vol 2, Issue 3, Oct / Nov
Published: 2005
Pages: p.114-119
Full text: Click here to order
Full text:
Click here to read online (Login Required)
Abstract: Diabetic nephropathy is the most common cause of
end stage renal failure (ESRF) in the developed world and as
the incidence of diabetes increases this trend will
continue, although most of these patients will die of
cardiovascular diseases. The renin-angiotensin system (RAS)
is believed to play a central role in the development and
progression of both micro- and macrovascular complications
of diabetes and blocking this system in diabetic patients is
critically important. Two widely used inhibitors of RAS are
angiotensinconverting enzyme (ACE) inhibitors and
angiotensin receptor blockers (ARBs). These drugs affect the
system at different levels and thus may have an additive
effect. Use of drugs from one class may not be completely
effective in blocking this system for several reasons. In
this article we discuss issues surrounding the use of dual
blockade (i.e. the use of ARB and ACE inhibitors together in
patients with diabetic nephropathy responding insufficiently
to previous antihypertensive treatment including either ARB
or ACE inhibitors) in patients with diabetes.
- Title: Should all diabetic patients receive
aspirin? Results from recent trials : commentary
Authors: Barwell, Nick; Marshall, Gillian; McDougall,
Claire; Brady, Adrian J.B.; Fisher, Miles
From: South African Journal of Diabetes and Vascular
Disease, Vol 2, Issue 3, Oct / Nov
Published: 2005
Pages: p.120-125
Full text: Click here to order
Full text:
Click here to read online (Login Required)
Abstract: A therosclerotic cardiovascular disease (CVD) is
common in patients with diabetes, and antiplatelet therapy
has been the cornerstone of preventative therapy for many
years. The majority of the evidence for the use of aspirin
in patients with diabetes comes from subgroup analysis of
major secondary prevention trials. Secondary prevention data
from the Antiplatelet Trialist's Collaboration meta-analysis
suggests that the benefit derived from aspirin is similar in
diabetic and non-diabetic populations. In the general
population, data from primary prevention studies have shown
the benefit of aspirin in terms of cardiovascular mortality,
but there is little evidence to suggest that aspirin is
beneficial in terms of total or cardiovascular mortality for
primary prevention in a diabetic population. Clopidogrel may
have advantages over aspirin and combined therapy may be
superior for certain types of coronary artery disease and
stroke, although this is offset by an increased risk of
haemorrhage in the latter setting. The use of aspirin in the
prevention of CVD in patients with diabetes should therefore
be focused on those with a history of vascular events or
aggressively treated hypertension.
- Title: Pioglitazone - an oral antidiabetic agent
and metabolic syndrome modulator. Can theory translate into
practice? : healthcare management
Authors: Campbell, Ian W.
From: South African Journal of Diabetes and Vascular
Disease, Vol 2, Issue 3, Oct / Nov
Published: 2005
Pages: p.128-135
Full text: Click here to order
Full text:
Click here to read online (Login Required)
Abstract: The metabolic syndrome, associated with insulin
resistance, is a cluster of cardiovascular risk factors
which results in premature morbidity and mortality from
atherosclerotic vascular disease. Pioglitazone, a peroxisome-proliferator-activated
receptor gamma (PPARg) agonist, is an insulin sensitiser
with the ability to address key features of the metabolic
syndrome: glucose intolerance including type 2 diabetes,
hypertension, dyslipidaemia, the pro-coagulant state,
endothelial dysfunction, inflammation and atherosclerosis.
The greatest potential benefit of pioglitazone is to
influence atherogenesis itself through its pleiotrophic
effects on vascular risk factors. This has been tested by
the PROactive study, results of which are published in
September 2005.
- Title: PROactive study shows reduced heart
attacks and strokes in type 2 diabetics on pioglitazone HCI
(Actos(R)) therapy : drug trends in diabetes
From: South African Journal of Diabetes and Vascular
Disease, Vol 2, Issue 3, Oct / Nov
Published: 2005
Pages: p.136-137
Full text: Click here to order
Full text:
Click here to read online (Login Required)
- Title: Comments from South African specialists
From: South African Journal of Diabetes and Vascular
Disease, Vol 2, Issue 3, Oct / Nov
Published: 2005
Pages: p.138
Full text: Click here to order
Full text:
Click here to read online (Login Required)
- Title: 1st scientific meeting of the
International Society of Diabetes and Vascular Disease, Ulm,
Germany, 11-13 May 2006
From: South African Journal of Diabetes and Vascular
Disease, Vol 2, Issue 3, Oct / Nov
Published: 2005
Pages: p.138
Full text: Click here to order
Full text:
Click here to read online (Login Required)
- Title: Opportunities to improve risk factor
control in type 2 diabetes and reduce cardiovascular events
: drug trends in diabetes
From: South African Journal of Diabetes and Vascular
Disease, Vol 2, Issue 3, Oct / Nov
Published: 2005
Pages: p.139-140
Full text: Click here to order
Full text:
Click here to read online (Login Required)
- Title: 19th World Diabetes Congress, Cape Town,
International Convention Centre, 3-7 December 2006
From: South African Journal of Diabetes and Vascular
Disease, Vol 2, Issue 3, Oct / Nov
Published: 2005
Pages: p.140
Full text: Click here to order
Full text:
Click here to read online (Login Required)
- Title: OneTouch(R) Ultra(R) rates best meter! :
drug trends in diabetes
From: South African Journal of Diabetes and Vascular
Disease, Vol 2, Issue 3, Oct / Nov
Published: 2005
Pages: p.141
Full text: Click here to order
Full text:
Click here to read online (Login Required)
- Title: Humalog(R) Mix50(TM) for type 2 diabetics
who require insulin and tighter glycaemic control : drug
trends in diabetes
From: South African Journal of Diabetes and Vascular
Disease, Vol 2, Issue 3, Oct / Nov
Published: 2005
Pages: p.142, 144
Full text: Click here to order
Full text:
Click here to read online (Login Required)
- Title: Three-quarters of diabetic patients
achieve ADA glycaemic targets with NovoMix(R) 30 : drug
trends in diabetes
From: South African Journal of Diabetes and Vascular
Disease, Vol 2, Issue 3, Oct / Nov
Published: 2005
Pages: p.144
Full text: Click here to order
Full text:
Click here to read online (Login Required)
- Title: Benefits of short- and long-acting
analogues stressed at EASD 2005 : drug trends in diabetes
From: South African Journal of Diabetes and Vascular
Disease, Vol 2, Issue 3, Oct / Nov
Published: 2005
Pages: p.146-147
Full text: Click here to order
Full text:
Click here to read online (Login Required)
- Title: Metformin still recommended as
first-choice treatment in type 2 diabetes: based on
cardioprotective benefits : drug trends in diabetes
From: South African Journal of Diabetes and Vascular
Disease, Vol 2, Issue 3, Oct / Nov
Published: 2005
Pages: p.148-150
Full text: Click here to order
Full text:
Click here to read online (Login Required)
- Title: Improvement in early chronic venous
insufficiency (CVI) on oral administration of red vine leaf
extract (Venavine) : drug trends in diabetes
From: South African Journal of Diabetes and Vascular
Disease, Vol 2, Issue 3, Oct / Nov
Published: 2005
Pages: p.151
Full text: Click here to order
Full text:
Click here to read online (Login Required)
- Title: South African journalist wins the Novo
Nordisk Media Prize :diabetes news
From: South African Journal of Diabetes and Vascular
Disease, Vol 2, Issue 3, Oct / Nov
Published: 2005
Pages: p.152
Full text: Click here to order
Full text:
Click here to read online (Login Required)
|
